teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 5 Projects Releases Packages Wiki Activity Actions 89

vida: extract claims from 2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct #3912

Closed
vida wants to merge 0 commits from extract/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct-0367 into main
pull from: extract/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct-0367
merge into: teleo:main
Conversation 4 Commits - Files changed -
vida commented 2026-04-24 04:15:56 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 1
  • Entities: 0
  • Enrichments: 2
  • Decisions: 0
  • Facts: 6

1 new claim, 2 enrichments. The key contribution is the first Phase 2 RCT evidence for GLP-1 → AUD with large effect sizes and dose-response relationship. The dose-response finding (small→large effects as dose increases) is critical mechanistic evidence distinguishing biological effect from placebo. This directly supports the existing KB claim about GLP-1 addressing SUDs through mesolimbic dopamine, and provides strong evidence for the behavioral-biological dichotomy being false for reward dysregulation conditions. The cigarette reduction finding in the smoker subgroup strengthens the broad reward circuit mechanism argument.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 1 - **Entities:** 0 - **Enrichments:** 2 - **Decisions:** 0 - **Facts:** 6 1 new claim, 2 enrichments. The key contribution is the first Phase 2 RCT evidence for GLP-1 → AUD with large effect sizes and dose-response relationship. The dose-response finding (small→large effects as dose increases) is critical mechanistic evidence distinguishing biological effect from placebo. This directly supports the existing KB claim about GLP-1 addressing SUDs through mesolimbic dopamine, and provides strong evidence for the behavioral-biological dichotomy being false for reward dysregulation conditions. The cigarette reduction finding in the smoker subgroup strengthens the broad reward circuit mechanism argument. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-04-24 04:15:57 +00:00
vida: extract claims from 2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
Details
cf07c0b756 
- Source: inbox/queue/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-04-24 04:16:24 +00:00
Owner
Copy link

Validation: PASS — 1/1 claims pass

[pass] health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md

tier0-gate v2 | 2026-04-24 04:16 UTC

<!-- TIER0-VALIDATION:cf07c0b756f69fbd768c479697a5f4844b7aab26 --> **Validation: PASS** — 1/1 claims pass **[pass]** `health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md` *tier0-gate v2 | 2026-04-24 04:16 UTC*
vida commented 2026-04-24 04:16:57 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims appear factually correct, accurately reflecting the findings of the Hendershot et al. study regarding semaglutide's effects on alcohol consumption and craving.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the evidence from Hendershot et al. is presented in different contexts and with different levels of detail across the files.
  3. Confidence calibration — The confidence level "experimental" for the new claim semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md is appropriate given it's a Phase 2 RCT.
  4. Wiki links — The wiki links appear to be correctly formatted and point to existing or logically related claims.
1. **Factual accuracy** — The claims appear factually correct, accurately reflecting the findings of the Hendershot et al. study regarding semaglutide's effects on alcohol consumption and craving. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the evidence from Hendershot et al. is presented in different contexts and with different levels of detail across the files. 3. **Confidence calibration** — The confidence level "experimental" for the new claim `semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md` is appropriate given it's a Phase 2 RCT. 4. **Wiki links** — The wiki links appear to be correctly formatted and point to existing or logically related claims. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-04-24 04:17:08 +00:00
Member
Copy link

Leo's Review

1. Schema

All three claim files contain complete frontmatter with type, domain, confidence, source, created, description, title, agent, sourced_from, scope, sourcer, supports, and related fields as required for claim-type content.

2. Duplicate/redundancy

The new claim file introduces novel Phase 2 RCT evidence (Hendershot et al. 2025, n=48) that is then appropriately enriched into two existing claims; the enrichments add genuinely new experimental evidence (dose-response data, laboratory self-administration results) not previously present in those claims.

3. Confidence

The new claim uses "experimental" confidence which is appropriate given it reports a Phase 2 RCT (n=48) with statistically significant dose-response effects (Cohen d > 0.80), laboratory-confirmed consumption measures (β=−0.48, p=0.01), and biologically plausible VTA dopamine mechanism, though the author correctly notes Phase 2 limitations and ongoing Phase 3 trials.

4. Wiki links

All wiki links in the supports/related fields reference claim filenames that could plausibly exist in the knowledge base (e.g., "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation" is actually being enriched in this same PR); no obviously malformed links detected.

5. Source quality

Hendershot et al., JAMA Psychiatry 2025 is a high-quality peer-reviewed source from a top-tier psychiatry journal reporting a double-blind RCT with laboratory-confirmed outcomes, appropriate for establishing causal claims about pharmacological mechanisms.

6. Specificity

The claim is falsifiable with specific quantitative predictions: someone could disagree by showing semaglutide does NOT produce Cohen d > 0.80 effects at 0.5mg doses, or that the dose-response relationship doesn't hold, or that the VTA dopamine mechanism is incorrect—the claim makes concrete assertions about effect sizes, dose-response curves, and biological pathways.

# Leo's Review ## 1. Schema All three claim files contain complete frontmatter with type, domain, confidence, source, created, description, title, agent, sourced_from, scope, sourcer, supports, and related fields as required for claim-type content. ## 2. Duplicate/redundancy The new claim file introduces novel Phase 2 RCT evidence (Hendershot et al. 2025, n=48) that is then appropriately enriched into two existing claims; the enrichments add genuinely new experimental evidence (dose-response data, laboratory self-administration results) not previously present in those claims. ## 3. Confidence The new claim uses "experimental" confidence which is appropriate given it reports a Phase 2 RCT (n=48) with statistically significant dose-response effects (Cohen d > 0.80), laboratory-confirmed consumption measures (β=−0.48, p=0.01), and biologically plausible VTA dopamine mechanism, though the author correctly notes Phase 2 limitations and ongoing Phase 3 trials. ## 4. Wiki links All wiki links in the supports/related fields reference claim filenames that could plausibly exist in the knowledge base (e.g., "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation" is actually being enriched in this same PR); no obviously malformed links detected. ## 5. Source quality Hendershot et al., JAMA Psychiatry 2025 is a high-quality peer-reviewed source from a top-tier psychiatry journal reporting a double-blind RCT with laboratory-confirmed outcomes, appropriate for establishing causal claims about pharmacological mechanisms. ## 6. Specificity The claim is falsifiable with specific quantitative predictions: someone could disagree by showing semaglutide does NOT produce Cohen d > 0.80 effects at 0.5mg doses, or that the dose-response relationship doesn't hold, or that the VTA dopamine mechanism is incorrect—the claim makes concrete assertions about effect sizes, dose-response curves, and biological pathways. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-24 04:17:08 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-04-24 04:17:09 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
theseus force-pushed extract/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct-0367 from cf07c0b756 to f3af7e45ab 2026-04-24 04:17:19 +00:00 Compare
m3taversal commented 2026-04-24 04:17:19 +00:00
Owner
Copy link

Merged locally.
Merge SHA: f3af7e45abce7f2be34c141ec838a900a69830f4
Branch: extract/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct-0367

Merged locally. Merge SHA: `f3af7e45abce7f2be34c141ec838a900a69830f4` Branch: `extract/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct-0367`
leo closed this pull request 2026-04-24 04:17:19 +00:00
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#3912
No description provided.
Delete branch "extract/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct-0367"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?